FY2025 · ended Dec 31, 2025 · Revenue $1.23M · Filed Mar 23, 2026
NRX Pharmaceuticals, Inc. (NRXP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 million and a net loss of $28.6 million. As of Jun 30, 2026 it held $26.7 million in cash and investments and $834,000 in total debt.
Revenue
$1.23M
Net income
$-28.62M
-13.9% vs prior year
Operating cash flow
$-14.11M
-32.7% vs prior year
Free cash flow
$-10.64M
+50.9% vs prior year
EPS
$-0.60
+69.7% vs prior year
Dividend per share
None
Shares outstanding
33.07M
+92.0% vs prior year
Net cash
$25.85M
as of Jun 30, 2026
Operating margin
-1324.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719406
- Former names
- Big Rock Partners Acquisition Corp. (until May 24, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0 | — | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | -$44.3M | -$115.8M |
| Net income | -$28.6M | -$25.1M | -$30.1M | -$39.8M | -$93.1M |
| Diluted EPS | — | — | — | -$0.60 | -$1.98 |
| Operating cash flow | -$14.1M | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Free cash flow | — | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Total assets | $13.0M | $3.7M | $7.3M | $25.8M | $32.7M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $18.4M | $11.9M |
| Stockholders' equity | -$15.9M | -$23.2M | -$11.7M | $7.4M | $20.8M |
| Cash and investments | $7.8M | $1.4M | $4.6M | $20.1M | $27.6M |
| Total debt | $631,000 | — | $9.2M | $2.8M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 5, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
All 477 NRX Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.